Margetuximab (MGAH-22) is a second generation anti-human epidermal growth factor receptor 2 protein (HER2) monoclonal antibody with anti-tumor activity for the study of metastatic HER2-positive breast cancer and for the synthesis of nanomedicines.
Purity:
95.00%
CAS Number:
[1350624-75-7]
Target:
EGFR|||HER
* VAT and and shipping costs not included. Errors and price changes excepted